12:00 AM
 | 
Jun 02, 2008
 |  BioCentury  |  Strategy

Focused mindset

By Susan Schaeffer Managing Editor

After about nine years of building a drug discovery and preclinical services business around rodent behavioral testing, PsychoGenics Inc. on Monday this week was set to announce Phase IIa results in ADHD for eltoprazine, a reprofiled compound in-licensed from Solvay S.A. However, PsychoGenics says this does not signal a shift in its focus toward clinical development. In fact, the company announced a new discovery services deal with Roche just last week.

"Our focus is not necessarily to take compounds into the clinic," CEO Emer Leahy told BioCentury. "We're a small company, and we believe we're pretty good at preclinical behavioral testing. Our intention is to stay focused on what we're good at and not allow clinical development to become our main focus."

Since the company's founding in 1999, its focus has been on the service side.

"We got started about nine years ago, when scientists at Yale, particularly Eric Nestler and Henry Jarecki, recognized the need for a company focused on behavioral testing in rodents," Leahy said.

Nestler is scientific co-founder of PsychoGenics, as well as chairman of its SAB and the Lou and Ellen...

Read the full 944 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >